NASSI, Luca
 Distribuzione geografica
Continente #
EU - Europa 162
NA - Nord America 116
AS - Asia 48
Totale 326
Nazione #
US - Stati Uniti d'America 114
IE - Irlanda 46
IT - Italia 31
SE - Svezia 27
DE - Germania 24
SG - Singapore 20
UA - Ucraina 17
HK - Hong Kong 14
IN - India 12
RU - Federazione Russa 9
NL - Olanda 4
CA - Canada 2
CN - Cina 1
CZ - Repubblica Ceca 1
FI - Finlandia 1
GB - Regno Unito 1
HU - Ungheria 1
IQ - Iraq 1
Totale 326
Città #
Dublin 46
Jacksonville 30
Hong Kong 14
Piemonte 14
Singapore 10
Wilmington 10
Dearborn 9
Chandler 7
Lawrence 6
Princeton 6
Dallas 5
Taranto 4
Elmas 3
Rimini 3
Berlin 2
Bremen 2
Cassano Magnago 2
Grafing 2
Menlo Park 2
San Mateo 2
Ann Arbor 1
Ashburn 1
Augusta 1
Baghdad 1
Boardman 1
Falkenstein 1
Houston 1
Jalandhar 1
Kunming 1
Milan 1
Monmouth Junction 1
Moscow 1
Novara 1
Nuremberg 1
Ottawa 1
Prague 1
Roasio 1
Santa Clara 1
Sopron 1
Toronto 1
Totale 199
Nome #
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 61
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score 60
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 58
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 47
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 38
null 37
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 34
Totale 335
Categoria #
all - tutte 2.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.224


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 0 0 15 5 0
2020/202142 5 0 5 0 5 1 5 7 5 4 5 0
2021/202239 0 2 0 9 3 0 2 0 2 1 9 11
2022/202391 6 5 11 0 6 6 5 1 47 0 2 2
2023/202436 2 2 4 2 5 0 4 0 0 2 9 6
2024/202549 1 5 6 2 3 0 1 12 14 5 0 0
Totale 335